Trial Profile
Phase III trial of dalbavancin in patients with complicated skin and skin structure infections caused by gram-positive bacteria
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2012
Price :
$35
*
At a glance
- Drugs Dalbavancin (Primary)
- Indications Gram-positive infections; Skin and soft tissue infections
- Focus Registrational; Therapeutic Use
- 17 Sep 2008 New trial record.